Geoffrey Purtill - Dec 1, 2021 Form 4 Insider Report for INVACARE CORP (IVC)

Role
SVP & GM, EMEA & Asia Pacific
Signature
/s/ Geoffrey Purtill, by Kristofer K. Spreen, his attorney-in-fact, pursuant to Power of Attorney dated November 24, 2021, on file with the Commission
Stock symbol
IVC
Transactions as of
Dec 1, 2021
Transactions value $
$0
Form type
4
Date filed
12/3/2021, 03:26 PM
Next filing
May 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IVC Common Shares Award $0 +5K +9.2% $0.00 59.4K Dec 1, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IVC Employee Stock Option (Right to Buy) 25.9K Dec 1, 2021 Common Shares 25.9K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in 1/3 annual increments over three years commencing on November 15, 2022.
F2 Includes 8,674 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan. 1,804 of these restricted stock units vest in full on May 15, 2022; 2,850 of these restricted stock units vest in 1/2 increments on May 15, 2022 and May 15, 2023; and 4,020 of these restricted stock units vest in 1/3 increments on May 15, 2022, May 15, 2023 and May 15, 2024.
F3 No transaction is being reported on this line. Reported on previously filed Form 3.
F4 The reporting person holds previously reported options to buy 25,911 Common Shares (with tandem tax withholding rights) under the Invacare Corporation 2003 Performance Plan and the Invacare Corporation 2013 Equity Compensation Plan, granted in reliance upon the exemption provided by Rule 16b-3. All options were granted between August 14, 2012 and March 16, 2017, at exercise prices between $12.15 and $14.49 per share, will expire between August 14, 2022 and March 16, 2027, and became exercisable between September 30, 2013 and December 31, 2019.